Achaogen (NASDAQ:AKAO) will be posting its quarterly earnings results before the market opens on Thursday, November 8th. Analysts expect Achaogen to post earnings of ($0.96) per share for the quarter.
Achaogen (NASDAQ:AKAO) last issued its earnings results on Monday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.19). The firm had revenue of $2.56 million during the quarter, compared to analyst estimates of $1.49 million. Achaogen had a negative return on equity of 146.50% and a negative net margin of 2,286.21%. On average, analysts expect Achaogen to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Shares of AKAO stock opened at $3.25 on Wednesday. The stock has a market capitalization of $169.08 million, a PE ratio of -1.03 and a beta of 0.67. The company has a quick ratio of 3.79, a current ratio of 3.79 and a debt-to-equity ratio of 0.42. Achaogen has a 1-year low of $3.20 and a 1-year high of $15.00.
Achaogen, Inc, a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.
Featured Article: Why do companies issue stock splits?
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.